These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36244857)

  • 1. Esophagitis and SARS-CoV-2 vaccine: Correspondence.
    Sriwijitalai W; Wiwanitkit V
    Med Clin (Barc); 2023 Feb; 160(3):137. PubMed ID: 36244857
    [No Abstract]   [Full Text] [Related]  

  • 2. Esophagitis after administration of the 1273-RNAm SARS-CoV-2 vaccine.
    Velilla Moliner J; Garcia Palacio J; Barberán Bernardos A
    Med Clin (Barc); 2022 Jul; 159(2):e13-e14. PubMed ID: 35279312
    [No Abstract]   [Full Text] [Related]  

  • 3. Immediate reactions after mRNA SARS-CoV-2 vaccination.
    Jeimy S; Wong T; Song C
    CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Yamamoto S; Fukunaga A; Tanaka A; Takeuchi JS; Inoue Y; Kimura M; Maeda K; Ueda G; Mizoue T; Ujiie M; Sugiura W; Ohmagari N
    Vaccine; 2022 Mar; 40(13):1924-1927. PubMed ID: 35183384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myopericarditis after administration of the Comirnaty© vaccine against SARS-CoV-2].
    Merenciano-González H; Marcos-Garcés V; López-Fornás F; Gabaldón-Pérez A; Bodi V
    Semergen; 2022 Oct; 48(7):101825. PubMed ID: 36122504
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2 vaccine safe for young patients.
    Onuora S
    Nat Rev Rheumatol; 2022 Oct; 18(10):552. PubMed ID: 35953559
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence.
    Deng Z; Zhang X; Liu Y; Xiao J; Zheng Y; Huang Y; Xu J
    Int J Surg; 2022 Apr; 100():106603. PubMed ID: 35314355
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin reaction after SARS-CoV-2 vaccines Reply to 'cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: A real-life multicentre experience'.
    Martora F; Villani A; Marasca C; Fabbrocini G; Potestio L
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e43-e44. PubMed ID: 35972802
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to "A commentary on "post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence" (Int J Surg 2022;100:106603)".
    Xu J; Zhang X; Deng Z
    Int J Surg; 2022 Sep; 105():106824. PubMed ID: 35987332
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
    Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
    Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody Response to SARS-CoV-2 mRNA Vaccine Among Kidney Transplant Recipients.
    Mungmunpuntipantip R; Wiwanitkit V
    Exp Clin Transplant; 2022 Nov; 20(11):1048. PubMed ID: 36524892
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute Coronary Syndrome After Inactivated SARS-COV-2 Vaccine.
    Panthong S; Vimonsuntirungsri T; Thapanasuta M; Wanlapakorn C; Udayachalerm W; Ariyachaipanich A
    Int Heart J; 2022; 63(2):388-392. PubMed ID: 35354757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience.
    Avallone G; Cavallo F; Astrua C; Caldarola G; Conforti C; De Simone C; di Meo N; di Stefani A; Genovese G; Maronese CA; Marzano AV; Parente R; Quaglino P; Roccuzzo G; Tassone F; Zalaudek I; Senetta R; Ribero S
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):e876-e879. PubMed ID: 35771093
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
    Werbel WA; Boyarsky BJ; Ou MT; Massie AB; Tobian AAR; Garonzik-Wang JM; Segev DL
    Ann Intern Med; 2021 Sep; 174(9):1330-1332. PubMed ID: 34125572
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.
    König M; Torgauten HM; Tran TT; Holmøy T; Vaage JT; Lund-Johansen F; Nygaard GO
    JAMA Neurol; 2022 Mar; 79(3):307-309. PubMed ID: 35072702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A commentary on "post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence" (int J surg 2022;100:106603).
    Mungmunpuntipantip R; Wiwanitkit V
    Int J Surg; 2022 Jul; 103():106664. PubMed ID: 35623601
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial.
    Wang G; Zhao K; Han J; Hu Z; Zhang T; Wang Y; Shi R; Li Y; Song Q; Du H; He P; Xu S; Yang X; Fu Y; Cui Y; Xie L
    J Infect; 2023 Feb; 86(2):154-225. PubMed ID: 36403700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.